Peptide education
Pancragen
Pancragen is a pancreas-themed tetrapeptide bioregulator, Lys-Glu-Asp-Trp in the papers and patents, AKS-P in Russian supplement capsules, KEDW on Western research vials. It is unusual in its family for having an actual human data point: a 2011 abstract reporting better fasting glucose and insulin-resistance measures in older type 2 diabetes patients. One old unreplicated abstract is also the ceiling of the human record, which has not stopped a weight-loss and GLP-1-stacking market from forming around the name.
Pancragen has a real early glucose signal, and it is old, abstract-level, and unreplicated. The internet increasingly sells it as a weight-loss peptide, a claim with no supporting evidence anywhere in its record.
Overview
Quick answer
The name can point to different things. Russian reference material describes Pancragen as a biologically active food supplement with 100 micrograms of peptide complex AKS-P in a 0.2 g capsule. The experimental literature often describes a Lys-Glu-Asp-Trp or Lys-Glu-Asp-Trp-NH2 tetrapeptide. Some Western vendors sell lyophilized research vials labeled KEDW or H-Lys-Glu-Asp-Trp-OH. Those are related references, but a capsule, paper, patent example, and research vial are not chemically interchangeable without identity details.
What is it?
A pancreas-focused ultrashort peptide from the Khavinson bioregulator family: Lys-Glu-Asp-Trp in the literature, AKS-P in Russian supplement capsules, KEDW or H-Lys-Glu-Asp-Trp-OH on Western research vials. Whether those are the same finished product is an open question.
What do people use it for?
The defensible claims cluster around glucose tolerance, fasting glucose, insulin-resistance measures, and chronic-pancreatitis remission support. The louder online claims, metabolic enhancement, GLP-1 stacking, pancreas regeneration, weight loss, have much less behind them.
What routes and amounts show up?
Short oral courses and short injection examples. The manufacturer report describes 1 to 2 capsules twice daily for 20 to 30 days in chronic-pancreatitis remission and 1 capsule twice daily for 20 days in type 2 diabetes, plus a conflicting 10-day tablet schedule. The patent describes 10 micrograms intramuscularly daily for 10 days. Western vials of 10 to 50 mg come with no human schedule.
Is it a weight-loss peptide?
No. Nothing in the Pancragen human record measured body weight as an outcome, and the approved obesity drugs people stack it against in forum threads are a different kind of evidence entirely. Pancragen's record is weak early glucose data, and that is all it is.
How should claims be separated?
By source and by product. The 2011 abstract is one thing, the manufacturer report another, the patent examples a third, and the research vials a fourth; none of them validates the others. Identity comes first, since AKS-P, KEDW, and the amidated and free-acid forms are not presented consistently.
Reported practice
Commonly reported protocol
Manufacturer capsule and tablet courses. Community-reported patterns, not verified by controlled human trials and not a use recommendation. Full use-pattern detail
Evidence
Evidence snapshot
A 2011 peer-reviewed abstract in older adults reported lower fasting glucose, better glucose-tolerance-test values, and reduced insulin and insulin-resistance measures in type 2 diabetes patients given Pancragen. The abstract lacked a modern full trial report or visible regimen detail.
The manufacturer-hosted clinical report and patent examples provide oral and intramuscular regimen descriptions, but they are not independent modern randomized-trial evidence.
Cell-culture papers, diabetic rat work, and old rhesus-monkey studies support biological interest in pancreatic signaling and glucose handling. Human pancreas repair and durable diabetes control need stronger patient-level evidence.
Russian supplement listings and Western research-use vial pages both use the Pancragen name, but the public descriptions differ in formula, terminal form, quantity, and identifiers.
The direct Pancragen safety record is limited, and FDA class-level materials on compounded or online peptide products remain relevant for injectable gray-market supply.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Anecdotal evidence | Verdict |
|---|---|---|---|---|
| Pancragen helps blood sugar or glucose tolerance. | The main human source is the 2011 peer-reviewed abstract. It reported fasting-glucose, glucose-tolerance-test, insulin, and insulin-resistance changes in older type 2 diabetes patients. A manufacturer-hosted report and patent examples also describe diabetes cohorts and glucose-related outcomes. | Rat diabetes studies, aged-monkey work, and pancreatic-cell marker papers make glucose and pancreatic endocrine questions biologically plausible. | Online demand includes metabolic-health and GLP-1 stacking interest, but the cited sources do not show a repeatable forum pattern for dose, route, cycle length, or outcome. | A limited early finding, not enough support to replace regulated diabetes care. |
| Pancragen repairs the pancreas or restores beta cells. | No strong human pancreas-repair or beta-cell restoration outcome is available. | Cell studies reported changes in pancreatic differentiation and activity markers such as Pdx1, Ptf1a, Pax6, Pax4, Foxa2, Nkx2.2, MMP2, MMP9, serotonin, Mcl-1, PCNA, Ki67, and p53. Those markers are worth tracking, but marker movement in cultured cells is not organ repair in people. | Vendor and bioregulator marketing can turn pancreas-marker language into broad regeneration claims. | The cell findings are not pancreas repair, regeneration, or beta-cell restoration evidence in people. |
| Pancragen treats chronic pancreatitis. | The main human support found here is a manufacturer-hosted report in chronic pancreatitis remission patients, where Pancragen was described as an adjunct to usual treatment with symptom, enzyme, laboratory-marker, and glucose improvements. | Pancreatic cell and endocrine-function studies fit the topic, but chronic pancreatitis outcomes remain unsettled. | Pancreas-support marketing may echo this claim, but the report is not a modern replicated trial. | Discuss only as weak company-hosted adjunctive evidence, not as an established pancreatitis therapy. |
| Pancragen is a weight-loss peptide. | The available Pancragen human materials reported no body-weight efficacy primary endpoint. That is very different from FDA-labeled obesity medicines where weight reduction is the central claim. | Glucose and pancreatic signaling can sound metabolically relevant, but that does not equal appetite suppression, obesity treatment, or reliable fat loss. | Reddit threads around GLP-1 stacking show demand and curiosity. They are not evidence that Pancragen itself causes weight loss. | No useful weight-loss support was found in the reviewed Pancragen sources. |
| Pancragen products are all the same. | This is a product-identity question, not a clinical outcome question. | Exact sequence, terminal form, salt form, dose format, and formulation matter when comparing supplement capsules, patent examples, papers, and research vials. | Vendor pages describe 10 mg, 20 mg, and 50 mg vials and sometimes cite public COAs or chemistry identifiers. Those listings conflict with one another and with the Russian AKS-P supplement description. | A capsule, patent example, and research vial each require product identity, route, and quality evidence before they can be compared. |
| Pancragen has a strong safety record. | The public human safety record is thin. The company-hosted report says no side effects, complications, or drug dependence were detected during its observation window, while Russian supplement material lists individual intolerance, pregnancy, and breastfeeding warnings. | Animal tolerability language and short-duration monkey work leave the larger human safety picture incomplete. | Research-use vial sellers may post purity claims, but sterility, endotoxin, potency, contamination, mislabeling, and wrong-active-ingredient questions remain. | Safety confidence is low, especially for gray-market injectable use. |
Bottom line
Main takeaway
Pancragen is a niche pancreas peptide with one small old glucose finding behind it. It is not an obesity drug, and it is not a proven pancreas-repair treatment.
Keep the Russian supplement, the old papers, the patent examples, and the research-vial market in separate columns: they share a name but differ in chemistry descriptions, doses, routes, and oversight.
The 2011 Korkushko abstract, the manufacturer-hosted 2007 report, and the patent examples carry the human record; rat, monkey, and cell-marker studies carry the biology. Verify chemistry before comparing anything: one vendor linked the name to a PubChem CID for an unrelated small molecule.
Identity
What it is
Pancragen is the Khavinson family's pancreas entry: a tetrapeptide described as Lys-Glu-Asp-Trp, positioned around pancreatic function, glucose handling, and metabolic aging.
It is unusual in this family for having a human data point at all. A 2011 peer-reviewed abstract reported lower fasting glucose, better glucose-tolerance-test values, and lower insulin and insulin-resistance measures in older type 2 diabetes patients. That is the peak: one abstract, no visible regimen, no replication since.
Around that peak sit a manufacturer-hosted clinical report with conflicting capsule and tablet schedules, patent examples with small intramuscular and oral groups, and preclinical work in pancreatic-cell cultures, diabetic rats, and old rhesus monkeys.
The market then dilutes all of it: research vials of 10 to 50 mg, formula conflicts, an amidated-versus-free-acid ambiguity, and at least one listing that ties the name to a PubChem identifier for an unrelated non-peptide molecule. "Pancragen" needs identity verification before it needs anything else.
How people talk about it online
Pancragen's online life has drifted from its evidence. Russian pharmacy listings and old bioregulator material discuss glucose and pancreatic support; Western vendor pages and Reddit threads increasingly frame it around metabolic enhancement and GLP-1 stacking, a use its record never touches.
The vendor layer supplies 10 to 50 mg vials, COAs, and mass-spec images, and also the warnings: formula conflicts between listings and one PubChem identifier pointing to an unrelated small molecule. Demand and risk are both documented here; benefit is not.
One caution for searchers: PancraGEN, the pancreatic-cyst DNA diagnostic test, is a completely different thing that shares the name. Check which one a page is about before reading further.
Use context
Routes, doses, and cycle patterns
The best-documented use patterns are short oral supplement-like courses and short intramuscular study examples. The 2011 human abstract reported metabolic outcomes without visible regimen detail. The manufacturer-hosted report and patent examples provide the most concrete route, amount, frequency, and duration language. Gray-market vendors sell much larger research vials; those listings show what is sold, not a public human-use schedule.
Human studies and product labels
2011 older-adult type 2 diabetes abstract
- Purpose
- Glucose tolerance and insulin-resistance measures
- Context
- Peer-reviewed human abstract
- Route
- Not stated in the abstract
- Amount
- Not stated in the abstract
- Frequency
- Not stated in the abstract
- Duration
- Not stated in the abstract
The abstract reported lower fasting glucose, improved glucose-tolerance test values, and reduced insulin and insulin-resistance measures in older type 2 diabetes patients, but the abstract lacks enough regimen or safety detail for a confident schedule comparison.
Manufacturer chronic-pancreatitis remission course
- Purpose
- Adjunctive chronic-pancreatitis remission support
- Context
- Company-hosted clinical report
- Route
- Oral
- Amount
- 1 to 2 capsules
- Frequency
- Twice daily with meals
- Duration
- 20 to 30 days
The report described Pancragen as an adjunct to usual treatment and reported symptom, enzyme, laboratory-marker, and glucose improvements. The source is company-hosted and is not an independent modern trial.
Manufacturer type 2 diabetes capsule course
- Purpose
- Glucose-related measures in type 2 diabetes
- Context
- Company-hosted clinical report
- Route
- Oral
- Amount
- 1 capsule
- Frequency
- Twice daily with meals
- Duration
- 20 days
This is one of the more concrete human-use descriptions, but it comes from a manufacturer-hosted report and appears alongside a different tablet schedule.
Manufacturer glucose-tolerance monitoring section
- Purpose
- Glucose-tolerance monitoring in type 2 diabetes
- Context
- Company-hosted clinical report
- Route
- Oral
- Amount
- 1 tablet
- Frequency
- Twice daily before meals
- Duration
- 10 days
The materials conflict between this 10-day tablet schedule and the 20-day capsule description. That matters when people try to extract a simple dose pattern from the report.
Patent intramuscular diabetes example
- Purpose
- Adjunctive diabetes example
- Context
- Patent example
- Route
- Intramuscular
- Amount
- 10 micrograms in 1 mL saline
- Frequency
- Once daily
- Duration
- 10 days
The patent described a mixed diabetes population, mostly insulin-treated, with a 16-patient adjunctive intramuscular arm. Patent examples can help recover historical regimen language, but they are not approval-grade clinical evidence.
Patent oral type 2 diabetes subgroup
- Purpose
- Type 2 diabetes subgroup example
- Context
- Patent example
- Route
- Oral
- Amount
- 100 microgram tablet
- Frequency
- Twice daily before meals
- Duration
- 10 days
The patent described a small four-person type 2 diabetes oral subgroup. The sample size is too small and the source is too weak for treatment claims.
Old rhesus-monkey endocrine-function studies
- Purpose
- Pancreatic endocrine function and impaired glucose tolerance
- Context
- Animal studies
- Route
- Intramuscular
- Amount
- 0.05 mg per day or 50 micrograms per animal per day
- Frequency
- Once daily
- Duration
- 10 days
These animal studies show why the compound is discussed around pancreatic endocrine function. They provide no human regimen.
Real-world discussion
Manufacturer capsule and tablet courses
- Purpose
- Pancreatic and metabolic discussion
- Context
- Manufacturer-hosted materials and bioregulator vendors
- Route
- Oral capsules or tablets in manufacturer materials
- Amount
- 1 to 2 capsules twice daily in the manufacturer capsule descriptions
- Frequency
- Twice daily in the manufacturer capsule descriptions
- Duration
- 20 to 30 days in manufacturer materials, alongside a conflicting 10-day tablet schedule
The cited sources do not show a repeatable forum pattern for dose, route, cycle length, or outcome. Informational context, not advice.
What varies
- Product identity: AKS-P capsule material, KEDW vial listings, free-acid sequence claims, and amidated patent or paper language may not refer to the same finished product.
- Goal: glucose tolerance, chronic-pancreatitis remission, pancreas-marker biology, and weight loss are different claims with different support.
- Route: oral supplement courses and intramuscular patent or animal examples are separate from research-vial use.
- Amount: references span 100 microgram capsule language, 10 microgram intramuscular examples, and 10 to 50 mg vendor vials.
- Product quality: a purity claim or COA leaves open identity, sterility, endotoxin, potency, storage, counterion, and wrong-ingredient risk.
Human data
Human evidence
Small, old, and never replicated. The strongest item is the 2011 Korkushko abstract: older type 2 diabetes patients with lower fasting glucose, improved glucose-tolerance-test values, and reduced insulin and insulin-resistance measures, and no visible regimen or safety detail. Behind it are a company-hosted 2007 report with conflicting schedules and patent examples with tiny subgroups. This is enough to justify a proper trial. It is not enough for diabetes-treatment, pancreas-repair, or weight-loss claims, and no weight endpoint appears anywhere in the record.
Evidence maturity
Pancragen has a real but unreplicated early glucose signal; it is far from an established metabolic or weight-loss therapy.
Pancreatic-cell differentiation-marker papers, diabetic rat studies, and aged-monkey work built the biological case.
A 2011 peer-reviewed abstract reported better fasting glucose and insulin-resistance measures in older type 2 diabetes patients, backed only by manufacturer-hosted and patent reports.
No modern independent randomized trial has replicated the early glucose or chronic-pancreatitis findings.
A Russian AKS-P supplement and Western research vials diverge on sequence, terminal form, and even chemistry identifiers.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| Korkushko et al. 2011 metabolic-disorders abstract | 30 healthy older adults and 33 older adults with type 2 diabetes | Peer-reviewed human abstract | Pancragen study material; the abstract reports outcomes but not the full regimen | The abstract reported lower fasting glucose, improved standard glucose-tolerance-test values, and reduced insulin concentration and insulin-resistance index in type 2 diabetes patients. | Abstract-level detail only; route, amount, duration, adverse-event capture, randomization, and replication are not adequately visible from the cited abstract. | weak |
| Manufacturer-hosted 2007 clinical report | Chronic-pancreatitis remission and type 2 diabetes cohorts | Company-hosted comparative report | Russian supplement / company material | The report described symptom, enzyme, laboratory, and glucose improvements and stated that no side effects, complications, or drug dependence were detected during the observed treatment window. | Company-hosted source, limited independent verification, adjunctive design, conflicting regimen descriptions, and no modern replicated trial record. | weak |
| Patent clinical examples | 36 diabetes patients, mostly insulin-treated, plus a small type 2 diabetes oral subgroup | Patent example | Patent material | The patent described intramuscular and oral use with claimed clinical-glucose benefit. | Patent examples are not peer-reviewed trials; the populations are mixed, the oral subgroup is very small, and independent replication has not been shown. | weak |
| Chronic pancreatitis remission claim | Chronic pancreatitis patients in remission | Company-hosted human report | Adjunctive supplement-style use | The company-hosted report described improvements in symptoms and clinical markers when Pancragen was added to usual treatment. | The source is not a modern independent trial, and the reported changes sit on top of usual treatment and manufacturer-linked material. | weak |
| Weight-loss evidence | No Pancragen weight-loss cohort located | No human weight-loss intervention trial found | Pancragen claims compared with obesity-drug evidence | The available Pancragen human sources reported no body-weight reduction primary outcome. | Pancragen lacks human outcomes evidence comparable to FDA-labeled obesity medicines. | anecdotal |
Cautions
Safety and unknowns
- Direct human safety reporting is thin. The company-hosted report says no side effects, complications, or drug dependence were detected, but that is not the same as a full modern safety program.
- Russian supplement material lists individual intolerance, pregnancy, and breastfeeding as warning-style exclusions.
- Long-term use, repeat courses, drug interactions, hypoglycemia risk in people already using glucose-lowering medicines, pancreatitis populations, pregnancy, breastfeeding, and pediatric use are not well characterized in the public Pancragen materials.
- Animal and cell studies do not settle human safety, especially for injected gray-market products.
- FDA warning letters and compounding safety pages are not Pancragen-specific, but they matter for online peptide sellers and products promoted under research-only language while implying human use.
Product quality
A vial label is only a starting point
Product identity is the central quality problem. Russian AKS-P supplement language, Lys-Glu-Asp-Trp-NH2 paper or patent language, H-Lys-Glu-Asp-Trp-OH COA language, and vendor formula claims diverge.
One vendor linked Pancragen to a PubChem CID for an unrelated non-peptide small molecule. That is an identifier warning, not a harmless typo.
Vendor COAs and mass-spec images can be useful, but independent lot testing is still needed for sterility, endotoxin, potency, storage, counterion, and wrong active-ingredient risk.
Research-use-only disclaimers leave enforcement and safety concerns in place when a site implies human drug use.
Identity
The product has to be distinguished as AKS-P, KEDW, Lys-Glu-Asp-Trp-NH2, H-Lys-Glu-Asp-Trp-OH, or something else sold under the same brand-like name.
Route and formulation
Oral supplement capsules, patent intramuscular examples, and lyophilized research vials raise different dose, handling, and risk questions.
Sterility and endotoxin
Purity or mass-spec identity cannot show injectable safety.
COA fit
A public COA may not match the shipped lot, may omit key tests, or may verify a different terminal form than the one assumed from the literature.
Intended-use language
Research-only language next to human-use signals can still make unapproved products with limited oversight look comparable to the studied material.
Mechanism
How it is proposed to work
The proposed mechanism is that an ultrashort pancreas-directed peptide may influence gene-expression and differentiation signals in pancreatic cells, especially in aging or diabetic-stress models. The papers argue that Pancragen nudges pancreatic cells toward more active, differentiated, or survival-favoring behavior.
Cell-culture papers reported increased expression of pancreatic differentiation factors including Pdx1, Ptf1a, Pax6, Pax4, Foxa2, and Nkx2.2 in young and aged pancreatic-cell cultures.
Another aged-cell paper reported changes in MMP2, MMP9, serotonin, CD79a, Mcl-1, PCNA, Ki67, and p53, which the authors interpreted as functional activity and survival-marker changes.
Independent pancreas-development literature makes markers such as PDX1, FOXA2, and PTF1A biologically relevant, but marker relevance cannot show clinical regeneration.
Broader Khavinson-group reviews describe ultrashort peptides as possible gene-expression modulators. That helps explain the research program, but the Pancragen clinical evidence remains much weaker than the mechanism evidence.
Pancragen (Lys-Glu-Asp-Trp) is a Khavinson-lineage tetrapeptide positioned for pancreatic and metabolic claims, with proposed effects on pancreatic-cell differentiation from the lineage's animal work.
FAQ
Common questions
What is pancragen?
Pancragen is a Khavinson-lineage bioregulator peptide positioned for pancreatic and metabolic claims. Its evidence is the Russian bioregulator literature plus animal and cell work.
What do bioregulator courses look like?
Manufacturer materials describe oral courses of 20 to 30 days, alongside a conflicting 10-day tablet schedule. The cited sources show no repeatable forum pattern for dose, route, or cycle length.
Is there human evidence?
Nothing meeting controlled-trial standards. The claims rest on the lineage's own publications.
Details
Technical details
Sources
References
- 1.
2011 older-adult metabolic abstract. Korkushko et al., “Prospects of Using Pancragen for Correction of Metabolic Disorders in Elderly People”
Peer-reviewed human abstract - Best human metabolic signal
- 2.
Pancreatic-cell differentiation study. “Effects of Pancragen on the differentiation of pancreatic cells”
Peer-reviewed cell study - Pancreatic differentiation markers
- 3.
Aging pancreatic-cell activity study. “Tetrapeptide stimulates functional activity of pancreatic cells in aging”
Peer-reviewed cell study - Activity and survival markers in aged cells
- 4.
Diabetic rat glucose study. “Effect of pancragen on blood glucose level, capillary permeability and adhesion in rats with experimental diabetes mellitus”
Peer-reviewed rat study - Preclinical glucose and endothelial findings
- 5.
Old-monkey endocrine study. “Impact of tetrapeptide pancragen on endocrine function of the pancreas in old monkeys”
Peer-reviewed primate study - Aged-monkey endocrine signal
- 6.
Old-monkey glimepiride comparison. “Correction of impaired glucose tolerance using tetrapeptide pancragen and glimepiride in old rhesus monkeys”
Peer-reviewed primate comparison - Comparative aged-monkey study
- 7.
Pancragen patent material. EP1697401 / US 7,491,703 patent material
Patent - Example regimens and identity form
- 8.
RLS Pancragen entry. RLS Pancragen official entry
Official Russian reference - Supplement status, composition, forms, manufacturer
- 9.
Russian pharmacy listings. Russian pharmacy listings
Retail listing - Current availability signal
- 10.
UK Peptides Pancragen listing. UK Peptides product page
Gray-market vendor page - Formula mismatch and market framing
- 11.
SwissChems Pancragen listing. SwissChems product page
Gray-market vendor page - Formula, PubChem mismatch, seller framing
- 12.
Limitless Life Pancragen listing. Limitless Life Nootropics product page
Gray-market vendor page - Alternate formula/metadata
- 13.
RawAmino Pancragen listing. RawAmino product page
Gray-market vendor page - Sequence form, purity claim, review signal, bac-water cross-sell
- 14.
RawAmino COA image. RawAmino public COA image
Vendor COA image - Public QC visibility
- 15.
RawAmino mass-spec image. RawAmino mass-spec image
Vendor QC image - Public QC visibility
- 16.
PubChem mismatch check. PubChem CID 68452887 search result
NIH chemistry database - Identifier mismatch check
- 17.
FDA SwissChems warning letter. FDA warning letter to SwissChems
FDA enforcement document - “Research chemical” disclaimer and enforcement risk
- 18.
FDA USApeptide warning letter. FDA warning letter to USApeptide.com
FDA enforcement document - Unapproved drug and contamination-risk language
- 19.
FDA compounding risk pages. FDA compounding safety-risk page and compounding Q&A
FDA regulatory pages - Class-level peptide quality and safety cautions
- 20.
Pancreatic transcription-factor references. Independent pancreatic transcription-factor references
Independent scientific context - Why PDX1, FOXA2, PTF1A matter biologically
- 21.
Wegovy prescribing information. Wegovy prescribing information
FDA label/source - Approved obesity comparator
- 22.
Zepbound prescribing information. Zepbound prescribing information
FDA label/source - Approved obesity comparator
- 23.
Reddit Pancragen experience question. Reddit thread asking about Pancragen evidence, experience, and product access.
Direct community evidence for interest and access questions without a reliable regimen